Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis

Current Opinion in Cardiology

Volumn 11, Issue 6, 1996, Pages 574-582

  Newby, Andrew C ^a   George, Sarah J ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CYTOLOGY; EXTRACELLULAR MATRIX; GENE THERAPY; GRAFT OCCLUSION; HEART INFARCTION; HUMAN; INTIMA; PRIORITY JOURNAL; REVIEW; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE FIBER;

EID: 0029803097     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199611000-00004     Document Type: Review

References (77)

1. Newby AC, George SJ: Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc Res 1993, 27:1173-1183.
2. George SJ, Williams A, Newby AC: An essential role for platelet- derived growth factor in neointima formation in human saphenous vein in vitro. Atherosclerosis 1996, 120:227-240. The authors detect an intimal-to-medial concentration of mRNA for PDGF α and β chains and PDGF protein in human saphenous vein organ cultures. Neointima formation is reduced by anti-PDGF antibodies without affecting VSMC proliferation, extending to humans the observations previously made in the rat.
3. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Preti PAM, Repetto S, De Servi S, Varani E: Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized, double-blind STARC study. Circulation 1994, 90:2710-2715.
4. Pazin MJ, Williams LT: Triggering signalling cascades by receptor tyrosine kinases. Trends Biochem Sci 1992, 17:374-378.
5. Glennon PE, Kaddouri S, Sale EM, Sale GJ, Fuller FJ, Sugden PH: Depletion of mitogen activated protein kinase using an antisense oligonucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res 1996, 78:954-961.
6. Newby AC, Lim K, Evans MA, Booth RFG: Inhibition of rabbit aortic smooth muscle cell proliferation by selective inhibitors of protein kinase C. Br J Pharmacol 1995, 114:1652-1656. A highly selective protein kinase C inhibitor was shown to inhibit with equal potency basal proliferation and responses to phorbol esters, PDGF, and PDGF plus 5-hydroxytryptamine. Complete inhibition of proliferation implies an essential role for this inhibitor in both basal and stimulated proliferation.
7. Abedi H, Zachary I: Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res 1995, 30:544-556.
8. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R: Insulin-like growth factor-1 and platelet-derived growth factor-BB Induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994, 93:1266-1274.
9. Pauly RR, Bilato C, Sollott SJ, Monticone R, Kelly PT, Lakatta EG, Crow MT: The role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation 1995, 91:1107-1115. The authors note the migration of proliferating but not quiescent VSMCs in response to PDGF correlates with the ability to initiate rapid calcium mobilization and activation of calcium- and calmodulin-dependent protein kinase II. Inhibitors of the enzyme, but not those for protein kinase C, inhibit migration of proliferating cells. Conversely calcium ionophores or gene transfer of a mutant-activated kinase II calcium- and calmodulin-dependent protein restores migration to quiescent cells. The paper thus presents convincing evidence for the involvement of this pathway in migration responses.
10. Bilato C, Pauly RR, Melillo G, Monticone R, Gorelick-Feldman D, Gluzband YA, Sollott SJ, Ziman B, Lakatta EG, Crow MT: Intracellular signaling pathways required for rat vascular smooth muscle cell migration: interactions between basic fibroblast growth factor and platelet derived growth factor. J Clin Invest 1995, 96:1905-1915. The authors show that antibodies to bFGF block the migratory response, calcium movements, and calcium- and calmodulin-dependent protein kinase II activation after PDGF treatment. These data amplify the conclusions of Pauly et al. (Circulation 1995, 91:1107-1115) that these intracellular events mediate the migration response and furthermore show that bFGF acts as an essential costimulant in these cells.
11. Fingerle J, Kraft T: The induction of smooth muscle cell proliferation in vitro using an organ culture system. Int Angiol 1987, 6:65-72.
12. Koo EWY, Gotlieb Al: Endothelial stimulation of intimal cell proliferation in a porcine aortic organ culture. Am J Pathol 1989, 134:497-503.
13. Angelini GD, Soyombo AA, Newby AC: Smooth muscle cell proliferation in response to injury in an organ culture of human saphenous vein. Eur J Vasc Surg 1991, 5:5-12.
14. Soyombo AA, Angelini GD, Bryan AJ, Newby AC: Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc Res 1993, 27:1961-1967.
15. Fingerle J, Tina Au YP, Clowes AW, Reidy MA: Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 1990,10:1082-1087.
16. Hedin U, Bottger BA, Forsberg E, Johansson S, Thyberg J: Diverse effects of fibronectin and laminin on phenotypic properties of cultured smooth muscle cells. J Cell Biol 1988,107:307-319.
17. Campbell JH, Campbell GR: Endothelial cell influences on vascular smooth muscle phenotype. Ann Rev Physiol 1986,48:295-306.
18. Southgate KM, Davies M, Booth RFG, Newby AC: Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J 1992, 288:93-99.
19. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A 1991,88:8154-8158.
20. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US: Inhibition of neointimal hyperplasia by blocking avb3 integrln with a small peptide antagonist GpenGRGDSPCA*. J Vasc Surg 1994, 19:125-134.
21. Matsuno H, Stassen JM, Vermylen J, Deckmyn H: Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994, 90:2203-2206.
22. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM: Alpha(v)beta(3) integrin expression in normal and atherosclerotic artery. Circ Res 1995, 77:1129-1135.
23. Newman CM, Bruun BC, Porter KE, Mistry PK, Shanahan CM, Weissberg PL: Osteopontin is not a marker for proliferating human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995, 15:2010-2018.
24. Schuppan D, Somsasundaram R, Dietrich W, Ehnis T, Bauer M: The extracellular matrix in cellular proliferation and differentiation. Ann N Y Acad Sci 1994,733:87-101.
25. Yabkowitz R, Mansfield PJ, Ryan US, Suchard SJ: Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J Cell Physiol 1993, 157:24-32.
26. Fager G, Camejo G, Olsson U, Östergren-Lundén G, Lustig F, Bondjers G: Binding of platelet-derived growth factor and low density lipoproteins to glycosaminoglycan species produced by human arterial smooth muscle cells. J Cell Physiol 1995,163:380-392.
27. Newby AC, Fabunmi RP, George SJ, Southgate KM, Banning AP, Thurston VJ, Williams A: Neointimal fibrosis in vascular pathologies: role of growth factors and metalloproteinases in vascular smooth muscle proliferation. Exp Nephrol 1995, 3:108-113.
28. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995, 77:863-868.
29. Yanagi H, Sasaguri Y, Sugama K, Monmatsu M, Nagase H: Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis 1992, 91:207-216.
30. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat Circ Res 1994, 75:539-545.
31. Bendeck MP, Irvin C, Reidy MA: Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996, 78:38-43.
32. Zempo N, Kenagy RD, Au T, Bendeck M, Clowes MM, Reidy MA, Clowes AW: Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid. J Vasc Surg 1994, 20:209-217.
33. Zempo N, Koyama N, Kenagy RD, Lea MJ, Clowes AW: Regulation of vascular smooth muscle cell migration and proliferation in vitro and injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996, 16:28-33.
34. Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995, 9:974-980.
35. Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC: Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem J 1996, 315:335-342. Stimulation of MMP-9 expression is shown to require synergistic interaction of PDGF and interleukin-1. This implies that a combination of injury, which causes PDGF production, and an inflammatory response leading to interleukin-1 production is the optimum stimulus for basement membrane degradation. By contrast, TIMP-I and -2 activity are not affected by these agents and TIMP-3 secretion is elevated by combinations of PDGF and TGF-β.
36. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Allpers CE, Clowes AW: Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol 1996, 148:777-783.
37. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
38. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG. Alpers CE, Clowes AW: Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995, 92:1393-1398.
39. Thompson RW, Holmes DR, Mertens RA, Liao SX, Botney MD, Mecham RP, Welgus HG, Parks WC: Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms-An elastolytic metalloproteinase expressed by aneurysm-inflltrating macrophages. J Clin Invest 1995, 96:318-326.
40. Li Z, Li L, Zielke R, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG: Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Path 1996, 148:121-128.
41. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH: In situ localisation and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol 1995, 15:1139-1144.
42. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix degrading proteinases. Proc Natl Acad Sci U S A 1995, 92:402-406. Macrophages isolated from the atherosclerotic plaques of cholesterol-fed rabbits are shown to express MMP-1, -2, -3, and -9. The results are confirmed by immunocytochemistry of arterial segments.
43. Shah PK, Falk E, Badimon JJ, Femandezortiz A, Mailhac A, Villareallevy G, Fallen JT, Regnstrom J, Fuster V: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995, 92:1565-1569.
44. Lendon CL, Davies MJ, Born GVR, Richardson PD: Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991, 87:87-91.
45. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 1995, 91:2125-2131.
46. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J 1995, 9:939-945.
47. Noda-Heiny H, Daygherty A, Sobel BE: Augmented urokinase receptor expression in atheroma. Arterioscler Thromb Vasc Biol 1995, 15:37-43.
48. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES: Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995, 15:1432-1443.
49. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO: Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995, 15:1444-1455.
50. Grainger DJ, Witchell CM, Watson JV, Metcalfe JC, Weissberg PL: Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor ß-like activity from serum. Cardiovasc Res 1993, 27:2238-2247.
51. Mii S, Ware JA, Kent KC: Transforming growth factor-beta inhibits human vascular smooth muscle cell growth and migration. Surgery 1993, 114:464-470.
52. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, Bush HL: Decreased type II/type I TGF-β receptor ratio In cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β. J Clin Invest 1995, 96:2667-2675. The VSMCs from human vascular lesions are shown to be lacking in the type II TGF-β receptor and in inhibitory growth responses to TGF-β. Gene transfer of the type II receptor into lesion cells restores inhibitory responses. The data imply that lesion VSMCs may have a paradoxically growth stimulatory response to TGF-β that leads to lesion progression.
53. Rasmussen LM, Wolf YG, Ruoslahti E: Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-beta activity. Am J Pathol 1995, 147:1041-1048.
54. Nikol S, Isner JM, Pickering JG, Keatney M, Leclerc G, Weir L: Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest 1992, 90:1582-1592.
55. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA: Production of transforming growth factor-β1 during repair of arterial injury. J Clin Invest 1991, 88:904-910.
56. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-β1 suppress Intimal hyperplasia in a rat model. J Clin Invest 1994, 93:1172-1178.
57. Nabel EG, Yang Z, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ: Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature 1993, 362:844-846.
58. O'Brien ER, Bennett KL, Garvin MR, Zderic TW, Hinohara T, Simpson JB, Kimura T, Nobuyoshi M, Mizgala H, Purchio A, Schwartz SM: βig-h3, a transforming growth factor-beta-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions. Arterioscler Thromb Vasc Biol 1996, 16:576-584.
59. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995, 1:74-79. The ratio of active to total TGF-β is shown to be reduced fivefold in men with triple coronary artery disease compared with normal volunteers. The activation of TGF-β correlates inversely with PAI-1 and lipoprotein(a) levels, implying that a failure of plasmin to activate TGF-β may be a common mode of action for these atherogenic risk factors.
60. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-beta is inhibited in transgenic apoliprotein(a) mice. Nature 1994, 370:460-462.
61. Blann AD, Wang JM, Wilson PB, Kumar S: Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 1996, 120:221-226.
62. Grainger DJ, Weissberg PL, Metcalfe JC: Tamoxifen decreases the rate of proliferation of vascular smooth muscle cells in culture by inducing production of transforming growth factor-β. Biochem J 1993, 294:109-112.
63. Kragel AH, Reddy SG, Wittes JT, Roberts WC: Morphometric analysis of the composition of atherosclerotic plaques In the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation 1989, 80:1747-1756.
64. Mautner SL, Mautner GC, Hunsberger SA, Roberts WC: Comparison of the composition of atherosclerotic plaques In saphenous veins used as aortocoronary bypass grafts with plaques in native coronary arteries in the same men. Am J Cardiol 1992, 70:1380-1387.
65. Bennett MR, Evan GI, Newby AC: Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-γ, heparin and cyclic nucleotide analogues and induces apoptosis. Circ Res 1994, 74:525-536.
66. Cho A, Courtman DW, Langille BL: Apoptosis (programmed cell death) In arteries of the neonatal lamb. Circ Res 1995, 76:168-175.
67. Bennett MR, Evan GI, Scwartz SM: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995, 95:2266-2274. Plaque-derived VSMCs show higher rates of apoptosis than cells derived from normal tissues, especially under serum-free conditions. Addition of PFGF and IGF-1 is shown to reduce rates of apoptosis, suggesting that they act as survival cytokines in vivo. Gene transfer of the bcl-2 gene into plaque VSMCs partially restores the low rate of apoptosis in normal VSMCs. However, bcl-2 is not detectable in either normal or plaque cells, implying that other pathways may normally prevent apoptosis in these cells. Nevertheless, the possibility of gene therapy with bcl-2 is still valid.
68. Kockx MM, Gambier BA, Bortier HE, DeMeyer GR, Declercq SC, Van Cauwelaert PA, Bultinck J: Foam cell replication and smooth muscle cell apoptosis in human saphenous vein grafts. Histopathology 1994, 25:365-371.
69. Geng Y-J, Libby P: Evidence for apoptosis in advanced human atheroma. Çolocalization with interleukin-1β-converting enzyme. Am J Pathol 1995, 147:251-266. The authors used DNA end-labelling to detect fragmentation in carotid and coronary plaques as an indicator of apoptosis. In normal media, 4% of cells stain positive compared with 30% in plaque cap VSMCs and (focally) up to 50% in foam cells abutting the lipid core. Colocalization with second marker of apoptosis, interleukin-1 converting enzyme, provides support for the idea that these very high apoptotic rates (which nevertheless remain a puzzle given plaque stability) can be measured in years.
70. Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G: Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol 1995, 147:267-277.-Similar findings as as Geng and Libby (Am J Pathol 1995, 147:251-266), together with data from balloon-injured rat iliac arteries. Provocative data show very high apoptotic rates (up to 50% on day 9 following balloon injury) that appear to imply an excess of cell death over proliferation at a time when the intima is still expanding.
71. Kockx MM, De Meyer GRY, Muhring J, Bult H, Bultinck J, Herman AG: Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis 1996, 120:115-124. Demonstrates low but detectable rates of apoptosis in the media and intima of cholesterol-fed rabbits. Apoptosis rates are much lower than proliferation rates, implying that apoptosis has a relatively minor effect on neointima formation.
72. Bochaton-Piallat ML, Gabbiani F, Redard M, Desmouliere A, Gabbiani G: Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol 1995, 146:1059-1064. In situ end-labeling is used to measure apoptotic rates in a rat aortic balloon injury model. High rates are confined to the most intimal cell layers and peak at 15 days, a time when lesion area may be declining.
73. Isner JM, Kearney M, Bortman S, Passeri J: Apoptosis in human atherosclerosis and restenosis. Circulation 1995, 91:2703-2711.
74. Kockx MM, Muhring J, Bortier H, De Meyer GRY, Jacob W: Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Am J Pathol 1996, 148:1771-1777.
75. Geng Y-J, Wu Q, Muszynski M, Hansson GK, Libby P: Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β. Arteriorscler Thromb Vasc Biol 1996, 16:19-27. Combinations of interferon gamma with interleukin-1 or TNF-α stimulate apoptosis of human and rat VSMCs, in part via a nitric oxide-dependent pathway.
76. Bennett MR, Evan GI, Schwartz SM: Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. Circ Res 1995, 77:266-273.
77. Katayose D, Wersto R, Cowan K, Seth P: Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells. Biochem Biophys Res Commun 1995, 215:446-451.